The ToGA trial has brought GC into the era of HER2-targeted therapy, and increasing numbers of HER2-targeted therapeutics have been widely studied in GC, yet most patients with advanced GC still inevitably experience disease progression or death due to resistance. Here, ERBB2 is linked to gastric cancer.